S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Public ClinicalTrials.gov record NCT01055301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide and lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, cisplatin, doxorubicin hydrochloride, cyclophosphamide, etoposide, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combining chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving bortezomib, thalidomide, and combination chemotherapy before and after transplant and lenalidomide after transplant may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying how well giving bortezomib, thalidomide, and lenalidomide together with combination chemotherapy and autologous stem cell transplant works in treating patients with newly diagnosed multiple myeloma.
Study identification
- NCT ID
- NCT01055301
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- bortezomib Drug
- cisplatin Drug
- cyclophosphamide Drug
- dexamethasone Drug
- doxorubicin hydrochloride Drug
- etoposide Drug
- lenalidomide Drug
- melphalan Drug
- thalidomide Drug
- gene expression analysis Genetic
- microarray analysis Genetic
- laboratory biomarker analysis Other
- autologous-autologous tandem hematopoietic stem cell transplantation Procedure
Drug · Genetic · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2011 (Type not available)
- Primary completion
- Jul 2011 (Actual)
- Completion
- Jul 2011 (Actual)
- Last update posted
- Mar 6, 2015
2011
United States locations
- U.S. sites
- 21
- U.S. states
- 4
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tulane Cancer Center Office of Clinical Research | Alexandria | Louisiana | 71315-3198 | — |
| Hematology-Oncology Clinic | Baton Rouge | Louisiana | 70809 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201-1379 | — |
| University of Mississippi Cancer Clinic | Jackson | Mississippi | 39216 | — |
| Island Hospital Cancer Care Center at Island Hospital | Anacortes | Washington | 98221 | — |
| St. Joseph Cancer Center | Bellingham | Washington | 98225 | — |
| Olympic Hematology and Oncology | Bremerton | Washington | 98310 | — |
| Highline Medical Center Cancer Center | Burien | Washington | 98166 | — |
| Columbia Basin Hematology | Kennewick | Washington | 99336 | — |
| Skagit Valley Hospital Cancer Care Center | Mount Vernon | Washington | 98274 | — |
| Harrison Poulsbo Hematology and Onocology | Poulsbo | Washington | 98370 | — |
| Harborview Medical Center | Seattle | Washington | 98104 | — |
| Minor and James Medical, PLLC | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Group Health Central Hospital | Seattle | Washington | 98112 | — |
| Swedish Cancer Institute at Swedish Medical Center - First Hill Campus | Seattle | Washington | 98122-4307 | — |
| University Cancer Center at University of Washington Medical Center | Seattle | Washington | 98195 | — |
| North Puget Oncology at United General Hospital | Sedro-Woolley | Washington | 98284 | — |
| Cancer Care Northwest - Spokane South | Spokane | Washington | 99202 | — |
| Evergreen Hematology and Oncology, PS | Spokane | Washington | 99218 | — |
| Wenatchee Valley Medical Center | Wenatchee | Washington | 98801-2028 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01055301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2015 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01055301 live on ClinicalTrials.gov.